Moleculin End Period Cash Flow vs Depreciation Analysis

MBRX Stock

USD 1.88 0.14 8.05%

Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech End Period Cash Flow and its Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

End Period Cash Flow vs Depreciation

End Period Cash Flow vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech End Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have strong relationship.

The correlation between Moleculin Biotech's End Period Cash Flow and Depreciation is 0.66. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's End Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Moleculin Biotech are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of End Period Cash Flow i.e., Moleculin Biotech's End Period Cash Flow and Depreciation go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

End Period Cash Flow

Depreciation

Depreciation indicates how much of Moleculin Biotech value has been used up. For tax purposes Moleculin Biotech can deduct the cost of the tangible assets it purchases as business expenses. However, Moleculin Biotech must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.Selling General Administrative is likely to drop to about 6.9 M in 2025. Issuance Of Capital Stock is likely to drop to about 180.4 K in 2025

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	222K	127K	114.3K	108.6K
Interest Income	240K	1.2M	1.1M	965.1K

Depreciation And Amortization Interest Income

Moleculin Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Property Plant And Equipment Net	Retained Earnings Total Equity
Total Assets		-0.28	0.65	0.67	0.99	0.81	0.76	-0.97	-0.77	0.72	0.98	0.76	0.04	0.98	0.84	-0.3	0.36	0.85	0.57	-0.76	0.98	-0.81	0.57	0.32	0.71	-0.87
Short Long Term Debt Total	-0.28		0.28	0.3	-0.36	0.2	-0.04	0.36	-0.26	0.31	-0.31	-0.17	-0.31	-0.31	0.01	0.15	0.11	0.13	0.2	0.18	-0.28	0.09	-0.18	-0.28	0.2	0.05
Other Current Liab	0.65	0.28		0.96	0.57	0.88	0.77	-0.52	-0.91	0.77	0.55	0.71	-0.03	0.55	0.85	-0.05	0.58	0.91	0.83	-0.71	0.57	-0.7	0.52	0.23	0.78	-0.76
Total Current Liabilities	0.67	0.3	0.96		0.57	0.88	0.82	-0.52	-0.95	0.88	0.56	0.75	0.07	0.56	0.9	-0.22	0.69	0.94	0.91	-0.74	0.59	-0.78	0.61	0.35	0.86	-0.82
Total Stockholder Equity	0.99	-0.36	0.57	0.57		0.77	0.67	-0.99	-0.68	0.6	0.99	0.69	-0.05	0.99	0.76	-0.24	0.22	0.79	0.44	-0.68	0.99	-0.71	0.45	0.21	0.59	-0.78
Net Tangible Assets	0.81	0.2	0.88	0.88	0.77		0.67	-0.76	-0.94	0.76	0.79	0.61	-0.27	0.79	0.87	-0.24	0.44	0.97	0.71	-0.6	0.8	-0.7	0.4	0.13	0.73	-0.8
Current Deferred Revenue	0.76	-0.04	0.77	0.82	0.67	0.67		-0.62	-0.79	0.84	0.63	0.86	0.39	0.63	0.87	-0.18	0.66	0.8	0.81	-0.85	0.66	-0.79	0.81	0.57	0.84	-0.88
Net Debt	-0.97	0.36	-0.52	-0.52	-0.99	-0.76	-0.62		0.67	-0.56	-1.0	-0.59	0.07	-1.0	-0.73	0.26	-0.21	-0.76	-0.4	0.58	-0.99	0.69	-0.42	-0.21	-0.57	0.78
Retained Earnings	-0.77	-0.26	-0.91	-0.95	-0.68	-0.94	-0.79	0.67		-0.89	-0.69	-0.72	0.01	-0.69	-0.95	0.34	-0.66	-0.97	-0.87	0.7	-0.72	0.82	-0.63	-0.37	-0.9	0.91
Accounts Payable	0.72	0.31	0.77	0.88	0.6	0.76	0.84	-0.56	-0.89		0.6	0.8	0.23	0.6	0.86	-0.33	0.66	0.84	0.84	-0.78	0.63	-0.86	0.69	0.44	0.94	-0.86
Cash	0.98	-0.31	0.55	0.56	0.99	0.79	0.63	-1.0	-0.69	0.6		0.6	-0.09	1.0	0.76	-0.27	0.23	0.79	0.43	-0.6	1.0	-0.7	0.43	0.2	0.6	-0.79
Non Current Assets Total	0.76	-0.17	0.71	0.75	0.69	0.61	0.86	-0.59	-0.72	0.8	0.6		0.37	0.6	0.8	-0.27	0.57	0.74	0.74	-1.0	0.63	-0.83	0.77	0.51	0.78	-0.8
Other Assets	0.04	-0.31	-0.03	0.07	-0.05	-0.27	0.39	0.07	0.01	0.23	-0.09	0.37		-0.09	0.18	-0.16	0.49	-0.06	0.32	-0.36	-0.06	-0.43	0.67	0.76	0.38	-0.28
Cash And Short Term Investments	0.98	-0.31	0.55	0.56	0.99	0.79	0.63	-1.0	-0.69	0.6	1.0	0.6	-0.09		0.76	-0.27	0.23	0.79	0.43	-0.6	1.0	-0.7	0.43	0.2	0.6	-0.79
Common Stock Total Equity	0.84	0.01	0.85	0.9	0.76	0.87	0.87	-0.73	-0.95	0.86	0.76	0.8	0.18	0.76		-0.46	0.75	0.96	0.9	-0.79	0.78	-0.89	0.8	0.59	0.92	-0.97
Common Stock Shares Outstanding	-0.3	0.15	-0.05	-0.22	-0.24	-0.24	-0.18	0.26	0.34	-0.33	-0.27	-0.27	-0.16	-0.27	-0.46		-0.62	-0.33	-0.47	0.26	-0.29	0.45	-0.54	-0.67	-0.4	0.45
Non Current Liabilities Total	0.36	0.11	0.58	0.69	0.22	0.44	0.66	-0.21	-0.66	0.66	0.23	0.57	0.49	0.23	0.75	-0.62		0.6	0.92	-0.56	0.27	-0.71	0.87	0.84	0.78	-0.72
Other Stockholder Equity	0.85	0.13	0.91	0.94	0.79	0.97	0.8	-0.76	-0.97	0.84	0.79	0.74	-0.06	0.79	0.96	-0.33	0.6		0.83	-0.73	0.81	-0.82	0.6	0.34	0.85	-0.9
Total Liab	0.57	0.2	0.83	0.91	0.44	0.71	0.81	-0.4	-0.87	0.84	0.43	0.74	0.32	0.43	0.9	-0.47	0.92	0.83		-0.72	0.47	-0.82	0.82	0.67	0.9	-0.84
Short Long Term Debt	-0.76	0.18	-0.71	-0.74	-0.68	-0.6	-0.85	0.58	0.7	-0.78	-0.6	-1.0	-0.36	-0.6	-0.79	0.26	-0.56	-0.73	-0.72		-0.62	0.81	-0.76	-0.5	-0.76	0.78
Total Current Assets	0.98	-0.28	0.57	0.59	0.99	0.8	0.66	-0.99	-0.72	0.63	1.0	0.63	-0.06	1.0	0.78	-0.29	0.27	0.81	0.47	-0.62		-0.73	0.47	0.23	0.63	-0.81
Short Term Debt	-0.81	0.09	-0.7	-0.78	-0.71	-0.7	-0.79	0.69	0.82	-0.86	-0.7	-0.83	-0.43	-0.7	-0.89	0.45	-0.71	-0.82	-0.82	0.81	-0.73		-0.81	-0.63	-0.93	0.92
Common Stock	0.57	-0.18	0.52	0.61	0.45	0.4	0.81	-0.42	-0.63	0.69	0.43	0.77	0.67	0.43	0.8	-0.54	0.87	0.6	0.82	-0.76	0.47	-0.81		0.91	0.83	-0.83
Other Liab	0.32	-0.28	0.23	0.35	0.21	0.13	0.57	-0.21	-0.37	0.44	0.2	0.51	0.76	0.2	0.59	-0.67	0.84	0.34	0.67	-0.5	0.23	-0.63	0.91		0.62	-0.63
Property Plant And Equipment Net	0.71	0.2	0.78	0.86	0.59	0.73	0.84	-0.57	-0.9	0.94	0.6	0.78	0.38	0.6	0.92	-0.4	0.78	0.85	0.9	-0.76	0.63	-0.93	0.83	0.62		-0.93
Retained Earnings Total Equity	-0.87	0.05	-0.76	-0.82	-0.78	-0.8	-0.88	0.78	0.91	-0.86	-0.79	-0.8	-0.28	-0.79	-0.97	0.45	-0.72	-0.9	-0.84	0.78	-0.81	0.92	-0.83	-0.63	-0.93

Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	29.0M	84.1M	57.4M	38.2M	43.9M	35.4M
Short Long Term Debt Total	277K	159K	451K	574K	660.1K	406.4K
Other Current Liab	1.7M	2.2M	2.6M	4.2M	4.8M	5.1M
Total Current Liabilities	2.9M	3.6M	4.8M	6.8M	7.8M	8.2M
Total Stockholder Equity	17.8M	79.0M	52.2M	26.1M	30.0M	28.9M
Net Tangible Assets	3.1M	4.4M	6.6M	67.8M	78.0M	81.9M
Net Debt	(14.9M)	(70.7M)	(42.7M)	(23.0M)	(20.7M)	(21.7M)
Retained Earnings	(56.9M)	(72.8M)	(101.8M)	(131.6M)	(118.4M)	(112.5M)
Accounts Payable	1.1M	1.4M	2.1M	2.5M	2.9M	1.5M
Cash	15.2M	70.9M	43.1M	23.6M	27.1M	22.4M
Non Current Assets Total	11.8M	11.6M	11.8M	11.9M	13.7M	11.4M
Non Currrent Assets Other	(11.8K)	338K	275K	(1.0)	(0.9)	(0.85)
Cash And Short Term Investments	15.2M	70.9M	43.1M	23.6M	27.1M	22.4M
Common Stock Shares Outstanding	656.4K	1.8M	1.9M	2.0M	1.8M	1.6M
Liabilities And Stockholders Equity	29.0M	84.1M	57.4M	38.2M	43.9M	35.4M
Non Current Liabilities Total	8.4M	1.5M	412K	5.3M	6.1M	6.4M
Other Stockholder Equity	74.5M	151.7M	154.0M	157.7M	181.3M	190.4M
Total Liab	11.3M	5.1M	5.2M	12.1M	14.0M	14.7M
Total Current Assets	17.2M	72.5M	45.6M	26.3M	30.2M	24.0M
Accumulated Other Comprehensive Income	65K	41K	12K	(9K)	(10.4K)	(9.8K)
Short Term Debt	118K	96K	116K	100K	90K	174.4K
Common Stock	29K	46K	69K	33K	38.0K	33.6K
Other Liab	1.4M	5.8M	8.2M	1.4M	1.6M	3.1M
Property Plant And Equipment Net	685K	445K	678K	796K	915.4K	512.3K
Inventory	1.9M	(45K)	(22K)	1.0	0.9	0.86
Other Current Assets	2.0M	1.1M	1.6M	2.6M	3.0M	3.2M
Property Plant And Equipment Gross	685K	1.1M	678K	1.7M	1.9M	2.0M
Property Plant Equipment	463K	603K	685K	445K	511.8K	412.9K
Net Invested Capital	17.8M	79.0M	52.2M	26.1M	30.0M	34.9M
Net Working Capital	14.3M	68.9M	40.8M	19.5M	22.4M	25.7M
Net Receivables	1K	45K	22K	99K	113.9K	119.5K
Capital Lease Obligations	277K	159K	451K	574K	660.1K	404.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Moleculin End Period Cash Flow vs Depreciation Analysis

End Period Cash Flow vs Depreciation

End Period Cash Flow vs Depreciation Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Depreciation

Moleculin Biotech fundamental ratios Correlations

Moleculin Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Moleculin Biotech fundamental ratios Accounts

Also Currently Popular

Additional Tools for Moleculin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Short Long Term Debt	- 1.0	Non Current Assets Total
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Retained Earnings Total Equity	- 0.97	Common Stock Total Equity